| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 731.80 | 5.3% | 13.1% |
| Total Income | 733.71 | 3.7% | 13.0% |
| Expenditure | 704.63 | 3.1% | 11.8% |
| PBT | 17.49 | 27.4% | 10.3% |
| Net Profit | 9.25 | 43.8% | 55.2% |
| OPM | 16.64% | 0.95pp | 2.42pp |
| NPM | 1.26% | 1.07pp | 1.92pp |
| EPS | 0.32 | 65.2% | 72.4% |
13% Revenue, 55% Profit Collapse: The Provision Gap HCG Won't Repeat
Revenue growth is solid and EBITDA is expanding, but reported profit crashed 55%. A ₹116 crore H1 EPCG provision and tax swing explain it — and the company's 'adjusted PAT' narrative sidesteps the real damage of a regulatory headwind arriving next quarter.
₹9.3 Cr
-55.2% YoY
₹116 Cr
~₹58 Cr Q2 impact
₹28.7 Cr
+30% YoY claimed
The headline reads like a disaster: profit down 55% despite revenue growing 13%. But the real story sits in two non-cash charges. A ₹116 crore EPCG (export promotion capital goods) provision in H1 and a ₹30 crore swing in tax accounting (deferred asset reversal from ₹99.6 Cr prior year) account for almost all of the PAT miss. Dig past management's 'adjusted' narrative — which claimed 30% H1 PAT growth to soften the GAAP blow — and you find operational profit actually did grow, but the exceptional items are material and front-loaded. The EPCG provision is retroactive and non-cash, so it won't recur, but it distorts the quarter and raises questions about management's transparency on one-time impacts.
The core tension: operational strength vs. reported weakness
The operating story is cleaner: EBITDA grew 17% and margin held stable at 19.7% (vs 19.2% prior year), confirming that the hospital network is executing well. North Bengaluru's losses narrowed to ₹6 Cr in Q2 (from ₹7.5 Cr in Q1), and the company added 25 operational beds in the quarter as it races toward a ₹520 crore bed expansion over FY28–29. Non-institutional revenue (higher-margin, premium payors) grew 21% and now represents 69% of the total, up from ~60% prior. Patient volumes rose 9% YoY and ARPP (average revenue per patient) grew 7%, both credible metrics for a 13% revenue outturn.
Management's claims vs. what holds up
Q2 revenue grew 16% on like-for-like basis (excl. Milann divested)
GAAP reported ₹731.8 Cr, +13.1% YoY
Contradicted (3pp miss)
EBITDA margin 19.7%, target 21–22% within 2 years
H1 EBITDA ₹274 Cr at 19.7% margin, stable trajectory
Supported, but new headwind
Adjusted PAT +30% growth H1
H1 adjusted ₹28.7 Cr vs ₹22.1 Cr prior; GAAP Q2 ₹9.3 Cr (−55%)
Overstated (obscures ₹116 Cr EPCG)
North Bengaluru on track to monthly EBITDA breakeven Q4 FY27
Q1 loss ₹7.5 Cr, Q2 loss ₹6 Cr; trajectory reasonable but not yet breakeven
Partial (ramp credible, execution-dependent)
Mid-teens revenue growth maintained; price cap offset via volume & mix
Q2 delivered 13.1% (low end); cap mechanisms untested; volume growth 9%
Conditional (offset not yet proven)
What changed on this call
How the street is positioned
HCG trades at ₹601, down 24.85% from its all-time high of ₹799.7 but up 17.09% off its 52-week low. The stock sits above its 20-day moving average (₹585.44) but below both the 50-day (₹650.14) and 200-day (₹624.51) averages, suggesting near-term support but longer-term uncertainty. RSI of 46.6 signals neutral momentum — no oversold bounce or overbought exhaustion yet. Volume is normal. The drawdown is material but not panic-driven.
Institutional ownership has been flat to slightly negative: FII holdings fell 0.01pp QoQ to 2.74% (down from a high of 3.59% two years ago), signaling consistent foreign fund retreat. DII added 0.29pp to 19.20%, suggesting domestic institutions are holding or nibbling but not accumulating aggressively. Promoter stake is locked at 64.21%, stable. The ownership structure shows no insider selling near the high, but foreign money is still leaving — a warning sign that the regulatory headwind and PAT volatility have dented confidence.
The stock's drawdown from the high is legitimate: price cap risk is new, PAT is volatile, and revenue growth is slower than the narrative suggested. But the absolute level — still 17% above the 52-week low — implies the market hasn't fully priced in either a recovery or a structural margin collapse. That's where the debate lives.
The bull-bear ledger
EBITDA +17%, margin stable at 19.7% — operational discipline intact despite regulatory noise
Non-institutional revenue +21%, now 69% of mix — deliberate shift to premium, higher-margin payors is working
Advanced therapies ramp (robotic surgeries +37% YoY, CAR-T, MR-LINAC) — differentiation in premium oncology segment
Reported PAT -55% YoY, leans 59% on provisions and tax adjustments — earnings quality flagged
Price cap on 137 oncology drugs effective Q3; offset mechanisms untested — near-term margin headwind real
North Bengaluru still loss-making ₹6 Cr Q2; path to breakeven Q4 credible but extends PAT drag
Revenue growth 13.1% vs claimed 16% — topline narrative softer than presentation
Ranked risks for a holder
Price cap on oncology drugs (₹137 drug list, 30% margin cap effective Q3)
HighMid-to-high single-digit EBITDA headwind annually on annualized basis. Offset mechanisms (volume, mix, efficiency) are real but untested under regulatory pressure. If volumes compress due to affordability concerns or payor shifts, margin compression could exceed guidance. Q3 earnings will be the first test.
PAT volatility from one-time charges (EPCG ₹116 Cr H1, tax swings)
HighGAAP PAT collapsed 55% despite operational strength. Management's 'adjusted PAT' narrative suggests limited transparency on exceptional items. Tax normalization is expected post-clarity on deferred assets, but if further provisions emerge, investor confidence in reported profits erodes further.
North Bengaluru ramp-up losses extending beyond Q4
MediumHospital targeting monthly EBITDA breakeven by Q4 FY27 (Jan–Mar quarter). Losses narrowed ₹7.5 Cr → ₹6 Cr but still material. Any delay extends PAT drag into FY28 and raises execution risk on capex productivity. Network synergy claims need validation.
Revenue growth deceleration: 13.1% delivered vs 16% claimed
Medium3pp gap suggests either lower underlying growth trajectory or persistent institutional payor mix headwinds. If institutional pullback continues and non-institutional growth slows, mid-teens guidance becomes a ceiling, not a floor.
Geopolitical headwinds on MVT (Medical Value Travel) — 4–5% of revenue, +25% growth but exposed
LowMVT growing at 25% YoY but management cited Middle East and Bangladesh disruptions offsetting growth. Diversification (Kenya, Kolkata, Nagpur) underway but visibility on sustainability of 25% growth unclear if geopolitical shocks repeat.
The debate
What to watch next
1 · Q3 FY27 EBITDA impact from price cap regulation
Management estimated mid-to-high single-digit EBITDA headwind. Q3 is the first full quarter after the cap takes effect (November 2026). Actual results will show whether volume growth (+9% Q2), ARPP trends (+7% Q2), and mix improvement (non-institutional +21%) are strong enough to offset. EBITDA margin compression vs 19.7% Q2 will signal success or warning.
2 · North Bengaluru monthly EBITDA breakeven by Q4 FY27
Hospital targeting Jan–Mar 2027 monthly breakeven. If achieved, it validates the ramp trajectory and provides visibility into FY28 PAT recovery (no more quarterly losses). Delay or further losses extend the margin/profit drag. Watch for commentary on infrastructure utilization, patient volumes, and ARPP at the new facility.
3 · Adjusted vs GAAP PAT reconciliation and tax normalization
Q3 will show whether PAT recovers toward the adjusted run-rate (~₹28.7 Cr H1 adjusted) or remains depressed. If new provisions or tax swings emerge, management's credibility on 'adjusted' metrics will erode. Watch for clarity on deferred asset realization timing and any further EPCG or exceptional items.
The single number to track
Adjusted EBITDA margin Q3 FY27. This quarter, it was 19.7%. Price cap regulations hit in Q3. If adjusted EBITDA margin (stripping out one-time items) stays at 19.7% or rises toward 20%, the company has proven it can offset the headwind. If it compresses to 19% or below, the bearish case (structural margin pressure, offset mechanisms failing) takes hold. That's the line in the sand for whether mid-teens revenue growth translates to margin expansion or margin defense.
HCG delivered a quarter that looks worse on paper than it is in reality — operational EBITDA is solid, the network is executing, and advanced therapies are differentiating the company in premium segments. But the stock's 24% drawdown from the all-time high is earned: reported profit collapsing 55% (even with good reasons), a new regulatory margin cap taking effect next quarter, and management's on-call optics (the 'adjusted' narrative) raising flags about transparency. This is not a crisis, but it's a compression cycle. The company enters a 2–3 quarter testing ground where assumptions about North Bengaluru breakeven, price cap resilience, and volume/mix offsets get validated or not. For holders, patience through Q3–Q4 is warranted; patience is not the same as complacency. For potential buyers, wait for Q3 price-cap proof points before re-rating up. Steady execution, not a step-change. Watch adjusted EBITDA margin; that's the tiebreaker.
13% growth, 55% PAT collapse; regulatory headwind looms
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Q2 delivered 13.1% growth, below claimed 16% on like-for-like basis. PAT miss of 55% YoY significant; management shifted to 'adjusted PAT' narrative, obscuring GAAP reality.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Revenue growth at 13.1% is mid-teens but softer than claimed (16% on adjusted basis). PAT crashed 55% due to regulatory provision (EPCG ₹116 Cr H1) and tax headwinds, masking underlying operational stability (EBITDA margin +84 bps). Regulatory trade margin caps kick Q3, adding near-term drag. Key risk: Price cap impact and competitive pressure on volumes/mix justify cautious near-term stance despite stable margins and multi-year growth trajectory.
₹731.8 Cr
Revenue · +13.1% YoY₹9.3 Cr
Reported PAT · −55.2% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
16% Q2 revenue growth excluding Milann
MISS13.1% YoY on GAAP reported basis (₹731.8 Cr)
EBITDA margin 19.7% with 17% growth
METEBITDA ₹142.5 Cr margin 19.5% consistent, delivery confirmed
Adjusted PAT 30% growth in H1
OVERSTATEDQ2 GAAP PAT ₹9.3 Cr down 55.2% YoY; H1 adjusted masks one-time charges
North Bengaluru ramp improving; target Q4 monthly EBITDA breakeven
PartialQ1 loss ₹7.5 Cr, Q2 loss ₹6 Cr; trajectory reasonable, not yet breakeven
Earnings quality
What changed since the last call
Regulatory trade margin cap introduced
New137 oncology drugs now capped at 30% margin; estimated mid-high single-digit EBITDA impact annually, effective Q3 onwards. Not in prior guidance.
Revenue growth guidance reaffirmed but delivered softer
DowngradeClaim: 16% Q2 growth (like-for-like excl. Milann). Delivered: 13.1% GAAP reported YoY. 3pp miss on topline vs narrative.
North Bengaluru losses narrowing; Q4 breakeven target
NeutralQ1 loss ₹7.5 Cr, Q2 loss ₹6 Cr. Management confident monthly EBITDA breakeven by Q4 FY27 (Jan 2027). Ramp on track but still diluting overall PAT.
The Q&A
Analysts pressed hard on price cap quantification, PAT decline, and growth deceleration. Management held firm on 'mid-teens' and deflected with 'adjusted' metrics. Q&A tone reflected measured confidence, not aggressive. North Bengaluru ramp defended as network synergy, not standalone. Q&A score: 6/10 (adequate, not transparent).
Price cap drug impact — Aditya Chheda, InCred Asset Management
PartialMid-to-high single digit percentage EBITDA impact annually. Effective Q3 (November). Multiple levers (volume, asset utilization, mix) to offset. No change to guidance.
North Bengaluru ramp — Devang Patel, Sameeksha Capital
AnsweredOn track to hit monthly EBITDA breakeven by Q4 FY27. Facility serves new micro-market, positive network synergy on KR Center. Ramp-up improving faster than prior hospitals.
Revenue growth guidance — Sumit Gupta, Antique Stock Broking
DodgedMid-teens guidance stands. Q2 inclusive of some headwinds (mix, regulation). Most clusters performing well; Gujarat deliberate pullback on low-margin payors. Expect gradual improvement.
EPCG provision impact — Aditya Chheda, InCred
AnsweredProvision covers all export obligations. No further material provisions expected. Provision is retroactive; does not impact current cash flow.
Cash flow and OCF conversion — Devang Patel, Sameeksha Capital
AnsweredTemporary: supplier credit terms extended (30 vs 90 days prior), ₹35 Cr AP Government subsidy timing, tax accrual increased. Normalized to ~54%. Expected to improve and revert closer to 80% as one-time items normalize.
Payor mix rationalization — Nitin Agarwal, DAM Capital
AnsweredConscious tradeoff. Non-institutional revenue grew 21% Q2 vs institutional 5%. Clinical talent, infrastructure, and marketing driving premium case mix. Gradual, not abrupt. Focus on sustainable margin expansion.
ARPP growth sustainability — Nitin Agarwal, DAM Capital
PartialCombination of higher robotic surgeries, high-end radiation therapies, payroll mix shift. Guidance reaffirms ARPP growth in line with inflation (~single digit) going forward. Growth across clusters expected to improve over time.
MVT (Medical Value Travel) growth — Gopal Bhatt, Baroda BNP Paribas
AnsweredFY26 ~3%, FY27 H1 ~4–5%, growing at 25% YoY. Geopolitical disturbance did impact, but HCG offsetting through improved screening and affordability messaging. Long-term structural tailwind on cancer incidence and quality care demand.
Guidance
Mid-teens (13–19%) revenue growth FY27 maintained
MediumQ2 delivered 13.1% (low end). Management reaffirmed guidance despite price cap headwind (Q3 effective). Conditional on volume resilience and mix improvement.
21–22% EBITDA margin target within 2 years; 24–25% by year 5
MediumCurrent 19.7% stable. Path to 21–22% requires volume growth + operational efficiency + price cap offset. Ambitious given regulatory headwind introduced post-Q1 guidance.
₹520 bed expansion FY28–29
MediumH1 capex ₹127.9 Cr noted; infrastructure and medical technology upgrades ongoing. Bed additions tracking on plan (25 in Q2, 146 H1).
Risks the call surfaced
Regulatory price cap
High137 oncology drugs (small subset of portfolio but including immunotherapy, high-margin segment) now capped at 30% margin. Estimated mid-to-high single-digit EBITDA impact on annualized basis; effective Q3 FY27.
North Bengaluru ramp-up
MediumHospital lost ₹7.5 Cr in Q1 FY27, ₹6 Cr in Q2. Path to monthly EBITDA breakeven by Q4 FY27 credible but execution-dependent. Any delay extends PAT drag.
PAT volatility from one-time charges
HighQ2 PAT collapsed 55% YoY (₹9.3 Cr) despite 13% revenue growth and stable EBITDA. EPCG provision (₹116 Cr H1), tax swing (₹30 Cr accrual vs ₹99.6 Cr deferred asset prior), and D&A burden responsible. Management's 'adjusted PAT' narrative (₹28.7 Cr H1, +30% growth) diverts from GAAP miss.
Revenue growth deceleration
MediumQ2 GAAP reported revenue growth 13.1% YoY (₹731.8 Cr) vs management claim of 16% on like-for-like basis (excluding Milann divested June 2026). 3 percentage point gap indicates either lower underlying growth or mix headwinds.
Geopolitical headwinds on MVT
LowMVT (Medical Value Travel) growing at 25% YoY but exposed to Middle East and Bangladesh geopolitical risks. Disruptions cited as partial offset to growth. Long-term tailwind but near-term visibility uncertain.
Management
Score 6/10. Moderately transparent. Management provided operational context and flagged regulatory headwind, but shifted to 'adjusted PAT' narrative to soften GAAP collapse. Disclosed one-time items (EPCG, tax swing) but minimized their materiality. Candid on payor rationalization strategy. Operational performance stable (EBITDA margin +84 bps) but revenue growth missed topline claim (13.1% vs 16% adjusted basis, 3pp gap). North Bengaluru ramp-up on trajectory but still loss-making. Bed capacity additions tracking plan (25 Q2, 146 H1). Prior guidance (mid-teens growth, 21–22% margin within 2yr) largely reaffirmed despite new regulatory headwind.
1 · Q3 FY27 (Oct–Dec 2026)
Trade margin cap on 137 oncology drugs effective; mid-high single-digit EBITDA headwind quantified
2 · Q4 FY27 (Jan–Mar 2027)
North Bengaluru target monthly EBITDA breakeven; validates ramp and visibility into FY28 profitability uplift
3 · FY28–29
₹520 bed expansion (Kenya, Kolkata, Nagpur, Bengaluru); capacity growth and geographic diversification underway
Key risk: Price cap impact and competitive pressure on volumes/mix justify cautious near-term stance despite stable margins and multi-year growth trajectory.